Tumor Mutational Burden as a Prognostic Biomarker in Follicular Lymphoma
These findings support the potential of TMB as a prognostic biomarker in FL, providing molecular understanding beyond established clinical indices and aiding in the identification of patients at higher risk of early progression following ICT.
Authors
- Joan Gibert (ORCID: https://orcid.org/0000-0002-0742-0759)
- Ramón Díez-Feijoo (ORCID: https://orcid.org/0000-0003-3137-3443)
- Maria Concepción Fernández-Rodriguez
- S. Pinzón (ORCID: https://orcid.org/0000-0002-2484-2582)
- Lierni Fernández‐Ibarrondo (ORCID: https://orcid.org/0000-0003-2612-0484)
- Blanca Sánchez‐González (ORCID: https://orcid.org/0000-0002-7651-5049)
- Raquel Longarón (ORCID: https://orcid.org/0000-0002-0515-9278)
- Nieves García-Gisbert (ORCID: https://orcid.org/0000-0002-8185-9786)
- Antonio Salar
- Antonio Gutiérrez
- Barbara Tazon-Vega
- Marta García-Recio
- Marta Lafuente
- Laura Camacho
- Junjie Ji
Institutions
- Universitat Pompeu Fabra (ES)
- Health Research Institute of the Balearic Islands (ES)
- Hospital Del Mar (ES)
Publication Details
- Journal
- Cancers
- Published
- 2026-02-25
- DOI
- https://doi.org/10.3390/cancers18050737
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences
- Instituto de Salud Carlos III